WATERS CORP (WAT)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for WAT
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| WAT | Independent Director | 62 | ["More than 25 years of experience in the pharmaceutical and medical device industries","Deep operational leadership experience in Asia-Pacific region's pharma and biopharma markets","Expertise in overseeing key business growth initiatives and partnerships","Knowledge on evolving complexities of Asia-Pacific region operations"] | ["Science and Technology"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| STAA | Member; Director; Special strategic advisor | 62 | ["More than 25 years of experience in the pharmaceutical and medical device industries","Experience with public company boards","Former Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC","Former Senior Vice President, China operations at AstraZeneca","Managing Director, China operations at Guidant Corporation","Various roles at Eli Lilly & Company including Marketing Director, China Operations"] | ["Science and Technology Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Independent Director since 2021 Age: 62 COMMITTEES Science and Technology Mr. Jiang s more than 25 years of experience in the pharmaceutical and medical device industries, with a particular focus in China and the Asia/Pacific region, allows him to bring an experienced international perspective to Board discussions on Waters growth strategy. Deep operational leadership experience and understanding of the greater Asia-Pacific region s pharma and biopharma markets, with a track record of successfully overseeing key business growth initiatives and partnerships. Contributes invaluable knowledge on evolving complexities of Asia-Pacific region operations, enhancing the Board s risk oversight of international expansion initiatives. CAREER HIGHLIGHTS Bayer AG EVP, President of Pharmaceuticals Region China and Asia Pacific (2015 2021), and President of Bayer Group Greater China Region (2019 2021) AstraZeneca plc SVP, GRA BU & Key Accounts (2011 2012), other senior management roles (2006 2010) Guidant Corporation Managing Director, China Operations (2004 2006) Eli Lilly & Company Various management roles (1999 2004) OTHER PUBLIC COMPANY BOARDS STAAR Surgical Company (NASDAQ: STAA) (March 2024 present) FORMER (PAST 5 YEARS) None EDUCATION BBA, Campbell University MA, Economics and Finance, Indiana State University